

North Central Cancer Treatment Group

N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Status Change – July 13, 2005

NOTICE OF STATUS CHANGE

Study 1, Arm C (EAC's patients) has met patient accrual for dose level 1. Therefore Study 1, Arm C (EAC's patients) is temporarily suspended to patient accrual effective July 13, 2005, 4:30 p.m. CST. Following this date/time, patient entry will not be permitted until further notification is issued.

Please retain this notice with the protocol.